



RNS Number : 8571P
Roquefort Therapeutics PLC
22 June 2022

22 June 2022

Roquefort Therapeutics plc
("Roquefort Therapeutics" or the "Company")

Issue of Warrants

Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company focused on early-stage opportunities in the biotechnology sector, announces the following issue of warrants to recently appointed Non-Executive Directors and an advisor to the Board:

Name	Position	Number of Warrants Issued	Total Number of Warrants Held After Issue
Ms Jean Duvall	Non-Executive Director	300,000	300,000
Dr Simon Sinclair ¹	Non-Executive Director	300,000	300,000
Prof. Trevor Jones	Board Advisor	300,000	300,000

¹Warrants held in the name of Livingstone Investment Holdings Ltd, a company in which Dr Sinclair has a beneficial interest

The warrants have been issued in relation to the appointment of the abovenamed earlier this year and form part of their annual remuneration package.

The warrants have a term of 5 years and are exercisable at a price of 15 pence, with 50% exercisable after 12 months and the balance exercise after 24 months.

Enquiries:

Roquefort Therapeutics plc

Stephen West (Chairman) +44 (0)20 3290 9339

Buchanan (Public Relations)

Ben Romney / Jamie Hooper / George Beale +44 (0)20 7466 5000

Optiva Securities Limited (Broker)

Christian Dennis

+44 (0)20 3411
1881

For further information on Roquefort Therapeutics, please visit www.roquefortplc.com and @RoquefortTherap on Twitter.

LEI: 254900P4SISIWOR9RH34

About Roquefort Therapeutics

Roquefort Therapeutics (LSE:ROQ) is a Main Market listed biotech company developing products through the pre-clinical phase prior to partnering or selling to big pharma. The Company is a pre-clinical biotech company focused on developing first in class Midkine targeting drugs for the treatment of cancer.

Through extensive research resulting in validation through publication in over 1,000 scientific journals, Roquefort Therapeutics has identified the potential to exploit the broad therapeutic potential of Midkine for a number of clinical indications of unmet needs. Roquefort Therapeutics holds an exclusive licence to the largest global IP portfolio on Midkine. The Midkine blocking drug development markets have significant global market potential (in the multi-billion dollars). Roquefort Therapeutic's pre-clinical program is currently underway with an initial focus on cancer.

This announcement contains inside information for the purposes of Article 7 of the UK version of Market Regulation (EU) No 596/2014 on Market Abuse as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended ("UK MAR").

The notifications below, made in accordance with the requirements of the UK MAR, provides further detail:

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

a) Name Jean Duvall

2 Reason for the notification

a) Position/status Non-Executive Director

b) Initial notification /Amendment Initial

3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name Roquefort Therapeutics plc

b) LEI 254900P4SISIWOR9RH34

4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a) Description of the financial instrument, type of instrument	Warrants (exercise price of 15 pence)	
Identification code	ISIN: GB00BMDQ2T15	
b) Nature of the transaction	Issue of warrants	
c) Price(s) and volume(s)	Price(s)	Volume(s)
	15 pence per share	300,000
d) Aggregated information		
- Aggregated volume	- 300,000	
- Price	- 15p	
e) Date of the transactions	22 June 2022	
f) Place of the transactions	Outside a trading venue	

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

1 Details of the person discharging managerial responsibilities / person closely associated

a) Name Simon Sinclair

2 Reason for the notification

a) Position/status Non-Executive Director

b) Initial notification /Amendment Initial

3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name Roquefort Therapeutics plc

b) LEI 254900P4SISIWOR9RH34

4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a) Description of the financial instrument, type of instrument	Warrants (exercise price of 15 pence)	
Identification code	ISIN: GB00BMDQ2T15	
b) Nature of the transaction	Issue of warrants	
c) Price(s) and volume(s)	Price(s)	Volume(s)
	15 pence per share	300,000
d) Aggregated information		
- Aggregated volume	- 300,000	
- Price	- 15p	
e) Date of the transactions	22 June 2022	
f) Place of the transactions	Outside a trading venue	

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please

contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

IOEDZGZVKZGGZZM

Anonymous (not verified)

Issue of Warrants

32768625

A

Wed, 06/22/2022 - 16:42

LSE RNS

Company Announcement - General

ROQ